Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #COVID19--Hologic's COVID-19 Tests Detect Omicron Variant

Hologic's COVID-19 Tests Detect Omicron Variant

Hologic has seen a strong 2021 as the pandemic has been with us longer than expected and certainly hope. While the 2022 guidance looks soft, exactly this reason will likely trigger a positive surprise.

Hologic: Still Going Strong

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic to Host Innovative Product Experiences and Medical Education Sessions On-site and Virtually at RSNA 2021

Hologic to Host Innovative Product Experiences and Medical Education Sessions On-site and Virtually at RSNA 2021

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic to Webcast Presentation at Upcoming Virtual Investor Conference

Hologic to Webcast Presentation at Upcoming Virtual Investor Conference

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic Announces European Launch of Genius™ Digital Diagnostics System for Cervical Cancer Screening

Hologic Announces European Launch of Genius™ Digital Diagnostics System for Cervical Cancer Screening

Impressive performance by the Breast Health and GYN Surgical segments drives Hologic's (HOLX) fiscal fourth-quarter revenues.

Hologic (HOLX) Q4 Earnings Surpass Estimates, 2022 View Dull

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #AAGL--Hologic to Launch the NovaSure® V5 Global Endometrial Ablation Device at Upcoming American Association of Gynecologic Laparoscopists Congress

Hologic to Launch the NovaSure® V5 Global Endometrial Ablation Device at Upcoming American Association of Gynecologic Laparoscopists 50th Global Congress

Hologic Inc (NASDAQ: HOLX) posted fourth-quarter revenues of $1.32 billion, down 2.3% Y/Y but beating analysts' average estimate of $1.04 billion. The drop in sales was driven by lower molecular diagnostic and COVID-19 assay sales.

Hologic Q4 Sales Fell On Lower COVID-19 Assay Sales; Guides FY22 Ahead Of Consensus

Hologic, Inc. (HOLX) CEO Stephen MacMillan on Q4 2021 Results - Earnings Call Transcript

Hologic (HOLX) delivered earnings and revenue surprises of 64.29% and 29.14%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Q4 Earnings and Revenues Beat Estimates

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic Announces Financial Results for Fourth Quarter of Fiscal 2021

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2021

Hologic (NASDAQ:HOLX) is set to give its latest quarterly earnings report on Monday, 2021-11-01. Here's what investors need to know before the announcement.

A Preview Of Hologic's Earnings

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #COVID19--Hologic's Multiplex COVID-19/Flu Test Now Commercially Available in North America and Europe

Hologic's Multiplex COVID-19/Flu Test Now Commercially Available in North America and Europe

Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its fourth-quarter performance.

Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?

The acquisition of Biotheranostics and the launch of new software are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the fourth quarter.

Breast Health Sales to Drive Hologic's (HOLX) Q4 Earnings

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #BRAD--Hologic Debuts Documentary-style Film Highlighting One Woman's Breast Cancer Journey Timed to Breast Reconstruction Awareness Day

Hologic Debuts Documentary-Style Film Highlighting One Woman's Breast Cancer Journey Timed to Breast Reconstruction Awareness Day

Hologic (HOLX) closed at $70.02 in the latest trading session, marking a +0.5% move from the prior day.

Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know

Hologic's (HOLX) recent acquisition will accelerate its growth and enhance patient outcomes by leveraging significant commercial resources and strong relationships with OB/GYN specialists.

Hologic (HOLX) to Expand Surgical Portfolio With Bolder Buyout

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic to Acquire Bolder Surgical for $160 Million, Expanding its Surgical Franchise

Hologic to Acquire Bolder Surgical for $160 Million, Expanding its Surgical Franchise

Hologic (HOLX) introduces the Novodiag system in Europe for on-demand testing of infectious diseases and antimicrobial resistance.

Hologic (HOLX) Launches Novodiag System for On-Demand Testing

In the latest trading session, Hologic (HOLX) closed at $69.95, marking a -1.99% move from the previous day.

Hologic (HOLX) Dips More Than Broader Markets: What You Should Know

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2021 on Monday, November 1, 2021

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2021 on Monday, November 1, 2021

MANCHESTER, England--(BUSINESS WIRE)--Hologic Launches Novodiag® System for On-Demand Molecular Testing in Europe

Hologic Launches Novodiag® System for On-Demand Molecular Testing in Europe

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #BCAM--Hologic Rings Nasdaq Opening Bell for 15th Time to Kick Off Breast Cancer Awareness Month

Hologic Rings Nasdaq Opening Bell for 15th Time to Kick Off Breast Cancer Awareness Month

Hologic (HOLX) expands Omni suite in EMEA with the new Omni 30 degree hysteroscope, Omni Lok cervical seal and Omni 5 French seal products.

News for Hologic Stock (HOLX)